We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

SeraNovo and Carna Biosciences Enter Second License Agreement for Development of Oral Formulation of Kinase Inhibitor

Product News   May 26, 2020

 
SeraNovo and Carna Biosciences Enter Second License Agreement for Development of Oral Formulation of Kinase Inhibitor

Credit: Unsplash

FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Arctoris Contributes Its Capabilities and Expertise to the Fight Against COVID-19

Product News

Arctoris has established a broad range of remotely accessible COVID-19 assays, including biochemical profiling for COVID-19 drug targets, as well as cellular and molecular assays conducted in its state-of-the-art robotic facility.

READ MORE

Sinovac COVID-19 Vaccine Collaboration Receives Approval for Phase III Trial

Product News

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced an update to its previously announced partnership with Butantan, a leading Brazilian producer of immunobiologic products and vaccines.

READ MORE

Aigenpulse Introduces Novel Data Intelligence Platform to Expedite Drug Discovery and Development

Product News

Aigenpulse has introduced a new state-of-the-art data intelligence platform that is designed to expedite the drug discovery and development process.

READ MORE

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE